MannKind Corporation (MNKD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

By
A A A

Summary:
MannKind's second quarter 2014 net loss of $0.19 per share was wider than the year-ago loss of $0.16 and the Zacks Consensus Estimate of a loss of $0.11 We believe that the numbers put out by MannKind in the second quarter of 2014 are not as significant as the deal with Sanofi on Afrezza. We are positive on MannKind's decision to choose a large company like Sanofi as a partner for Afrezza. Sanofi's marketing muscle should go a long way in making the U.S. launch (expected in the first quarter of 2015) of Afrezza a success. The deal will result in a substantial inflow of cash at MannKind. We remain Neutral on the stock.

Overview:

Valencia, CA-based MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for diseases such as diabetes. In Jun 2014, the company's first product, Afrezza was approved for the improvement of glycemic control in adults suffering from diabetes mellitus. The FDA has approved the drug for administration in diabetes patients before each meal or within 20 minutes after its commencement.

Afrezza's approval comes with several limitations. For type I diabetes patients, Afrezza must be used in combination with long-acting insulin. Also, the drug is not recommended for the treatment of diabetic ketoacidosis and for patients who smoke. Afrezza even carries a boxed warning stating that there is a risk of acute bronchospasm in patients suffering from chronic lung disease. Afrezza's approval also comes with a Risk Evaluation and Mitigation Strategy to ensure that the benefits of Afrezza overshadow the risks of acute bronchospasm in patients suffering from chronic lung disease. The FDA has also asked for several post-marketing studies for the drug.

The pathway to approval was not smooth as the FDA had earlier issued two complete response letters (CRL) for Afrezza. While issuing the second CRL, the FDA asked the company to conduct two phase III trials (Affinity 1 and Affinity 2) with the next-generation inhaler.

Results from the first study (Affinity 1) revealed that non-inferior decreases in A1c levels were observed in Afrezza treated patients compared to the insulin aspart group. Afrezza was found to be well tolerated during the study. Results from the second study (Affinity 2) revealed that the primary objective of superior reductions in A1c levels from baseline was observed in the Afrezza group compared to the comparator oral-therapy group. Moreover, more patients under the Afrezza group reached specified A1c target levels compared to those in the comparator oral-therapy group. The candidate was generally well tolerated in this study as well.

Afrezza utilizes MannKind's proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company's MedTone inhaler, a small, easy-to-use pulmonary delivery system. Once inside the lungs, the insulin is rapidly absorbed into the bloodstream. MannKind has developed Afrezza to produce a profile of insulin level in the bloodstream that approximates the insulin level normally seen in healthy individuals following the beginning of a meal, but absent in diabetic patients.

Apart from Afrezza the company does not have any significant candidate in its pipeline. In 2012, the company out-licensed two of its developing oncology programs.

In Jun 2009, MannKind acquired Pfizer's insulin factory at Frankfurt, Germany for $30 million. The deal involved the purchase of assets related to the production of bulk insulin, including the relevant property rights, production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery.

On Nov 13, 2012, MannKind signed a license agreement with Colby Pharmaceutical Company granting the latter exclusive rights to its early stage cancer programs. In Apr 2012, MannKind signed an exclusive agreement with Tolero Pharmaceuticals, enabling the latter to develop and market compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program. The BTK program is focused on the development of treatments for hematological malignancies and inflammatory diseases. MannKind could receive up to $130 million in the form of upfront as well as milestone payments from the agreement.


MannKind Corporation (MNKD): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MANNKIND CORP (MNKD): Free Stock Analysis Report

To read this article on Zacks.com click here.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Stocks

Referenced Stocks: CRL , MNKD

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

100%
86%

Most Active by Volume

7,344,618
  • $102.485 ▲ 0.23%
7,062,477
  • $49.6764 ▲ 0.50%
6,074,021
  • $16.07 ▲ 0.37%
5,954,122
  • $52.48 ▲ 15.88%
5,287,024
  • $19.19 ▲ 0.37%
4,868,159
  • $17.452 ▼ 8.72%
4,398,547
  • $34.829 ▲ 0.52%
3,895,516
  • $74.23 ▲ 0.51%
As of 8/29/2014, 10:06 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com